Up-regulation of hexokinase II contributes to rituximab-chemotherapy resistance and is a clinically relevant target for therapeutic development
Juan Gu(Roswell Park Comprehensive Cancer Center), Francisco J. Hernandez‐Ilizaliturri(Roswell Park Comprehensive Cancer Center)
Cited by 48
Related Papers
Pirtobrutinib after a Covalent BTK Inhibitor in Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2023|213
Hodgkin Lymphoma, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2020|153
Hodgkin Lymphoma Version 1.2017, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2017|142
NCCN Guidelines Insights: Non-Hodgkin's Lymphomas, Version 3.2016
|Journal of the National Comprehensive Cancer Network|2016|141
PIM1 phosphorylates and negatively regulates ASK1-mediated apoptosis
|Oncogene|2009|119